Mehdi Mirsaeidi, M.D.
- Fax: 305-575-3412
- American Board of Internal Medicine
- American Board of Internal Med-Pulmonary Disease
- Internal Medicine
- Pulmonary Disease - Internal Medicine
- Assistant Professor of Division of Pulmonary and Critical Care
- Director of Sarcoidosis Program
We are interested in studying novel biomarkers that are involved in the context of sarcoidosis, a rare disease with high morbidity and mortality. We and others have shown that pulmonary fibrosis is a major cause of mortality. Our ongoing studies are aimed at A) understanding sarcoidosis mechanisms by using translational research, B) finding new biomarkers in diagnosis and treatment of sarcoidosis , and C) determining new strategies to improve health equality in sarcoidosis.
A list of publication of our team may be found here.
2015 Advanced Pulmonary and Critical Care Fellowship
University of Illinois at Chicago
2011 Internal Medicine Residency
University of George Washington-Providence Hospital
- Metabolomics: Applications and Promise in Mycobacterial Disease.
- Gender susceptibility to mycobacterial infections in patients with non-CF bronchiectasis.
- Association of serum TNF-a, IL-8 and free light chain with HLA-DR B alleles expression in pulmonary and extra-pulmonary sarcoidosis.
- Sarcoidosis in the national veteran population: association of ocular inflammation and mortality.
- Racial difference in sarcoidosis mortality in the United States.
- Efficacy Results of a 52-week Trial of Adalimumab in the Treatment of Refractory Sarcoidosis.
- Nontuberculous mycobacterial disease mortality in the United States, 1999-2010: a population-based comparative study.
Dr. Mirsaeidi graduated with high honors and distinction from his medical school in Iran and completed a Master of Public Health, residency, and fellowship in Infectious Diseases there. He was a Chief Resident and won several honors nationally and internationally. During this residency and fellowship, he distinguished himself by completing several large clinical research projects. He had a leading role in the first clinical trial for multidrug resistant tuberculosis treatment in Iran. He continued these activities when he came to the United States in 2006. He joined the group of Dr. Julio Ramirez in Division of Infectious Diseases at the University of Louisville. He was acknowledged for his contributions in clinical research in pulmonary infection in 2007 and 2008. He published several articles with significant impact in pneumonia including introducing thrombocytosis as a marker for poor outcome in patients with community-acquired pneumonia and IBMP-10 as a prognostic tool for patients with ventilator-associated pneumonia.
After completing an Internal Medicine residency, h
After completing an Internal Medicine residency, he joined the University of Illinois at Chicago (UIC) as a pulmonary and critical care fellow in July 2011. He immediately began two clinical research projects on nontuberculous mycobacterial infection, including one on bronchiectasis, and sarcoidosis He also continued his research in tuberculosis. He developed first sarcoidosis clinical dataset in UIC and performed several translational projects on fibrosing pulmonary sarcoidosis. He is also concerned about health disparities and climate change. He recently joined the University of Miami and has been developing the UM sarcoidosis program.